Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.61 USD | -1.74% | -2.32% | -8.36% |
05-23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
05-23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.36% | 1.49B | |
+13.33% | 9.15B | |
+48.35% | 4.65B | |
-20.52% | 4.58B | |
+7.99% | 4.07B | |
+7.59% | 2.24B | |
-25.72% | 2.21B | |
+12.16% | 2.03B | |
-41.98% | 1.82B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals : Jefferies Lifts Supernus Pharmaceuticals to Buy From Hold, Price Target to $40 From $25